Search Orphan Drug Designations and Approvals
-
| Generic Name: | Self complimentary adeno-associated virus serotype 9 expressing human aspartoacylase transgene |
|---|---|
| Date Designated: | 12/23/2019 |
| Orphan Designation: | Treatment of Canavan Disease |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Aspa Therapeutics, Inc. 421 Kipling Street Palo Alto, California 94301 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







